Apogee's Zumilokibart Hits Key Endpoints in Atopic Dermatitis Trial, Eyes Phase 3
Event summary
- Apogee's Phase 2 APEX trial Part B met all primary and secondary endpoints with mid-dose zumilokibart achieving 65.9% EASI-75 response vs. 23.4% placebo.
- Mid-dose zumilokibart demonstrated robust efficacy across all lesional and itch endpoints with a favorable safety profile.
- Apogee plans to advance mid-dose zumilokibart into Phase 3 trials in 2H 2026, pending regulatory interactions.
- Strategic financing collaboration with Blackstone Life Sciences announced to fund zumilokibart's development through commercialization.
The big picture
Apogee's positive Phase 2 results for zumilokibart in atopic dermatitis position the company to compete in the large and underserved inflammatory and immunology markets. The strategic financing collaboration with Blackstone Life Sciences underscores the potential of zumilokibart as a pipeline-in-a-product opportunity across multiple indications. The focus on less frequent dosing and robust efficacy could set a new standard of care for patients with moderate-to-severe atopic dermatitis.
What we're watching
- Regulatory Pathway
- Whether Apogee can secure regulatory approval for Phase 3 trials as planned in 2H 2026.
- Competitive Positioning
- How zumilokibart's differentiated dosing regimen and efficacy profile will position it against existing and emerging therapies in atopic dermatitis.
- Pipeline Expansion
- The pace at which Apogee advances zumilokibart into asthma and eosinophilic esophagitis indications.
Related topics